

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number  
**WO 03/076667 A1**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/70**

(21) International Application Number: PCT/HU03/00020

(22) International Filing Date: 10 March 2003 (10.03.2003)

(25) Filing Language: Hungarian

(26) Publication Language: English

(30) Priority Data:  
P0200981 14 March 2002 (14.03.2002) HU

(71) Applicants and

(72) Inventors: **JENEY, Csaba** [HU/HU]; Úri u. 31, H-1014 Budapest (HU). **TAKÁCS, Tibor** [HU/HU]; Nagy-Somlyó u. 6, H-2080 Pilisjászfalu (HU).

(74) Agent: **SZENTPÉTERI, Zsolt**; S.B.G. & K. Patent and Law Offices, Andrásy út 113, H-1062 Budapest (HU).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: AMPLIFICATION-HYBRIDISATION METHOD FOR DETECTING AND TYPING HUMAN PAPILLOMAVIRUS

(57) Abstract: The present invention provides amplification and hybridisation method for detecting and typing human papillomavirus (HPV), and the primers and hybridisation probes used in the method. The invention relates to a concrete part of the HPV genome, which is suitable for designing HPV genus-specific and HPV genotype-specific hybridisation oligonucleotide probes.



**WO 03/076667 A1**

Amplification – hybridisation method for detecting and typing  
human papillomavirus

5

**Field of the Invention**

In the present invention method is provided for improved detection and genotyping human papillomavirus (HPV).

10 One aspect of the invention defines HPV genomic regions, which are suitable for designing HPV genus-specific and HPV genotype-specific hybridization oligonucleotide probes, advantageously are close to each other and in one amplicon.

Another aspect of the invention relates to the sequences of  
15 the genus-specific and genotype-specific probes.

Another aspect of the invention relates to optimised formulation of reagents and method, which is suitable to amplify and detect an expanded set of HPV genotypes („kit”).

20 **Background of the invention**

Numerous papillomavirus sequences were determined, see the publications incorporated herein by reference: HPV-6: de Villiers et al., J. Virology, 40 (1981); HPV-11: Dartmann et al., Virology 151, 124-130 (1986); HPV-16: Seedorf et al., Virology  
25 145, 181-185 (1985); HPV-18: Cole and Danos, Journal of Molecular Biology 93, 599-608 (1987); HPV-31: Goldsborough et al., Virology 171, 306-311 (1989); HPV-33: Cole and Streeck, J.

Virology, 58, 991-995 (1986); HPV-54: Favre et al., J. Cancer 45, 40-46 (1990); HPV-56: Lőrincz, J., Gen. Virol. 70, 3099 (1989).

5 Detecting and typing of HPV is reported in a number of publications, besides Southern blotting and other hybridisation techniques, the most widely used techniques are the PCR-based methods, since these methods simultaneously provide high sensitivity, specificity and the flexibility of the assay gives more control to comply the analytical requirements.

10 Human papillomavirus, a member of the *Papillomaviridae* family, is a DNA tumorvirus, with an 8000 bp of circular genome. The virus shows strong epithelial tropism, and proliferates only in differentiated epithelial cells. The papillomavirus has suspected etiologic role in many different  
15 human diseases, for example in different skin diseases, i.e. in verruca, condyloma acuminatum and skin tumours and in other conditions, such as cervical carcinoma, anogenital carcinomas, laryngeal carcinoma. It is well established that the human papillomavirus shows strong correlation with the incidence of  
20 these tumors, and this is even true for the pre-cancerous lesions (CIN, VIN, VAIN, PIN, PAIN). HPV can be detected in 99% of the cervical carcinoma patients. This close statistical relationship is possibly caused by the causal role of the HPV in the formation of cervical carcinoma. On the basis of the  
25 epidemiological data, the patients to be infected by different HPV genotypes do not have the same level of risk to develop cervical carcinoma. According to these findings the genotypes

are classified into low risk, medium risk and high risk classes, and besides these there are not-classified genotypes too. Since the risks are grossly different and the incidence of the HPV infection is very high, the determination of genotype is of great  
5 importance.

The HPV virus can not be cultivated. The serological diagnosis of HPV infection is limited to detect the exposure to the virus (past or present infection), but can not exactly identify the genotype, the role is mostly limited to epidemiological  
10 investigations.

For papillomaviruses, exact serologic classification (serotyping) does not exist genotyping is the widely accepted classification method. These can be divided into two groups, according to whether detection is preceded by amplification or  
15 not. In one embodiment of the latter method, full length genomic RNA probes are used to detect the denatured HPV DNA genomes, and the heteroduplex is detected with specific antibodies (Hybrid Capture – Digene). According to another method, Southern blot technique is used for detection and  
20 genotyping the HPV genotypes. The disadvantage of these methods is the relative insensitivity and partial lack of specificity. In the case of the Hybrid Capture method many publications report different cross-reactions, causing false positive reactions in clinical conditions. The authors reported  
25 that the cross-reactions were acceptable only with a cut-off control of high (1 ng/ml) DNA concentration, which underlines the non-desirable coupling between sensitivity and specificity.

By the amplification methods this problem does not appear, since the reaction responsible for the sensitivity (amplification) is carried out separately.

Generally the amplification techniques differ in the selected  
5 amplified genome segment, number of primers, and the applied detection technique. The most frequently used primers are the GP5+ - GP6+, MY9-MY11 and the different type-specific PCR reactions.

The most frequently used detection techniques are the  
10 sequence-specific hybridisation, restriction fragment length polymorphism (RFLP) and the line probe assay (LiPA). Besides these ones, sequencing of amplicons and thymidine pattern generated by dUTP incorporation is used, but less frequently.

The analytical characteristics of the amplification  
15 techniques vary in wide ranges. The methods can be characterized by the amplifiable genotypes, the analytical sensitivity of the genotype amplification and the specificity and reliability of the detection. In this field the MY9-MY11 degenerated primer system is considered to be the reference  
20 reaction. In case of the MY9-MY11 system LiPA hybridisation detection system exists (Innogenetics). The major drawback of the MY9-MY11 system it is difficult to control the degenerated synthesis of the primers that is why the relative ratio of the primer species produced in the synthesis is varying from  
25 synthesis to synthesis, which can result in the unpredictable changes of the analytical behaviour of the PCR reaction; secondly, this reaction can amplify the fewest types, compared

to the other widespread used reactions. It is well known from the literature, that the system can amplify genotype 51 only in that case, if the HPV genotype 51 type-specific primers are added to the reaction. Using degenerate primer synthesis the  
5 relative ratio of the primer species can not be changed, and it is impossible to tailor the primer ratios to achieve better analytical performance and a balanced amplification of genotypes.

The GP5+ - GP6+ reaction solves the problem only by the use of two carefully selected pair of primers - optimised to the  
10 genital HPV sequences - the two primer systems are easy to manage , however the flexibility is lower. The GP5+ - GP6+ system can amplify a lot of known HPV genotypes, but the analytical characteristics of the system are not optimal (sensitivity is not balanced with different genotypes), and the  
15 two primer approach is constrained in optimisation , e. g. balancing the detection sensitivities for the individual genotypes is highly problematic (except the limited optimisation of the melting temperature and concentration of the  $MgCl_2$ ). It is difficult to adapt the GP5+ - GP6+ system to the amplification of  
20 other genotypes, which in any case influence its future application, since the need for detecting new genotypes permanently occur. The identification of the genotypes is not solved adequately.

Another well known wide genotype-specific amplification  
25 method is the L1C method: two-primer system, with two versions, one is using (with the LC1 primer) the L1C2 or the newL1C2 primer, to amplify further genotypes. The detailed

description of the L1C amplicon can be found in the literature [Jpn. J. Cancer Research 82, 524-531 (1991)].

- Basically two criteria must be fulfilled by the detection postamplification methods: routine diagnostic applicability (simplicity, costs, time), and the requirement of power of discrimination suitable level of discrimination power. A significant group of methods are not suitable in terms of power of discrimination discrimination power. Therefore the application of the RFLP is limited, because of the short amplified regions, there are not enough diagnostic restriction sites, so often the genotypes can only be classified into groups. Another example the SSCP technique is difficult to refer the complex patterns of the SSCP to genotypes, and also, the robustness of these reactions is not satisfactory, either.
- The power of discrimination is especially important from the diagnostic point of view to fulfil the requirements of the regulatory authorities. From the aspects of the simplicity and the power of discrimination sequencing is the ideal approach, since its automation is solved and able to detect each genotypes (or even subtypes thereof), if the sample is not a mixture of genotypes. But in the practice it is not widely used, because it is expensive and time-consuming, and its application in routine diagnostic laboratories is not acceptable, and in case of mixed samples none of the genotypes can be determined.
- The advantage of the hybridisation methods is that their power of discrimination or stringency can easily be changed, since several parameters of the reaction can be varied in wide ranges,

and some forms are easily automated, the reaction is less expensive, and in case of parallel implementation (with some forms) even the time needed is insignificant.

Therefore there is a need for a new HPV  
5 amplification/detection method, which eliminates the disadvantages of the current methods, and it is cheap, easy to reproduce and automate. The invention describes an amplification and hybridisation assay, in which the primers are independently synthesized molecules, therefore their relative  
10 ratio can easily be controlled and optimised, and the amplification has a balanced sensitivity. Hybridisation reactions carried out in highly parallel manner comply with the criteria of a low cost, fast, flexible and automatable reaction.

### 15 **Summary of the invention**

In one aspect the present invention provides/defines a human papillomavirus genomic regions, which is inside a consensus amplicon (that is a region, which is amplifiable with primers binding to conserved sequences flanking the amplicon).  
20 wherein these genomic regions are characterised having genotype specific DNA sequence, which is suitable to design genotype specific hybridisation probes.

In Another aspect, the invention provides/defines an another HPV genomic region in this consensus amplicon,  
25 wherein these genomic regions are characterised having HPV genus specific, conserved DNA sequence, which is suitable to design genus specific hybridisation probes.



An essential element the invention is the presence of two genomic segments inside one consensus amplicon, which are suitable for designing genus and genotype specific hybridisation probes.

5 In Another aspect, the invention provides the use of primers in amplification reaction, the DNA sequences and concentrations of which, and the conditions of the reaction-cycle to be optimised for the balanced sensitivity amplification of the human papillomavirus genotypes.

10 The present invention provides methods for detecting and genotyping the human papillomavirus (HPV), wherein the methods comprise the steps of:

a) nucleic acid molecules isolated from biological samples are amplified with the primer mixture of the invention, and as  
15 a result double-stranded, amplified products are produced, which

b1) are either hybridised in stringent conditions with the HPV genus specific hybridisation probe, or with a mixture thereof, and the presence of HPV consensus amplicon  
20 present in a given case are detected;

and/or

b2) are hybridised in stringent conditions with a mixture of the genotype specific hybridisation probes provided by of the invention, and the corresponding HPV genotype-  
25 groups are detected;

and/or

b3) are either hybridised in stringent conditions with a type-specific hybridisation probe of the invention or a mixture of thereof, and the HPV genotype present in a given case are detected and determined.

5 In summary the method provided in present invention can be used for the amplification/detection of a given group of the HPV genotypes, resulting in the detection of HPV genomic DNA thereof with genus specific probes, and the collective (grouped) or individual genotyping of the HPV genomes. The method can  
10 be used to access the risk or to determine those individuals who are at risk of later conditions and diseases, caused or associated by the HPV viruses found in the patients, at a given time, and especially with the type-specific detection thereof. The method provided by the invention is also suitable to screen for the  
15 presence of HPV in a given population and also to augment, support or confirm a cytological diagnosis in a given individual (screening).

#### Detailed description of the invention

20

To aid in understanding the invention, several terms are defined below.

The terms "nucleic acid" and "oligonucleotide" refer to probes, primers, and other short DNA, RNA, PNA (peptide  
25 nucleic acid) and other chemical oligomers, which are capable of sequence-specific binding on DNA, RNA or PNA template (target molecule).

The term "hybridisation" refers to the sequence-specific binding of two nucleic acid sequences. The conditions used significantly determine the stringency of hybridisation, therefore hybridisation can occur under less stringent conditions, even if  
5 the nucleic acids are not exactly complementary. In some cases it could be necessary that the nucleic acid probe bind to a group of sequences, which are closer or farther relatives of each other. Those skilled in the art of nucleic acid technology can determine the conditions, which if fulfilled, then binding is suitably specific  
10 or aspecific.

The term "probe" refers to a set of oligonucleotides, which show sequence-specific hybridisation in the presence of complementary and partially complementary nucleic acids. The structure of the oligonucleotides can be modified, to make  
15 execution of the steps following hybridisation possible, or to change their hybridisation properties.

The term "type-specific probe" refers to a set of oligonucleotides, which under stringent conditions bind only to the target region that is exactly complementary with them.  
20 Hybridisation conditions suitable for this requirement are well known in the art (see, e.g., Sambrook et al., 1985, Molecular Cloning Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. USA). Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting  
25 point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the probe is associated in the

presence of the suitable complementary target molecule. Relaxing the stringency of the hybridising conditions (for example raising salt concentration or lowering temperature) will allow bindings of not exactly complementary sequences. In case  
5 of not exactly complementary template, the nucleotides, which can not bind to the template nucleic acid in the template are the „mismatch nucleotides”.

The term "primer" refers to nucleotides, capable of acting as a point of initiation of DNA synthesis (priming) under  
10 conditions in which synthesis of a primer extension product complementary to a nucleic acid strand is induced on a nucleic acid template, i.e., in the presence of four different nucleoside triphosphates and an agent for polymerisation (i.e., DNA polymerase or reverse transcriptase) in an appropriate buffer  
15 and at a suitable temperature. A primer is preferably a single-stranded DNA molecule. The appropriate length of a primer typically ranges from 15 to 40 nucleotides. A primer does not need to reflect the exact sequence of the template, therefore by changing the temperature of the binding (reaction) group of  
20 similar target molecules can serve as template for the synthesis (consensus amplicon). Chemical groups with certain advantageous characteristics can be used to label the primer oligonucleotide, to make it capable for binding to solid phase and for other purposes.

25 The term "primer" – in the present invention - also refers to a group of sequentially related oligonucleotides, wherein the group of oligonucleotides is capable for priming (as described

above) on a certain group of template sequences. Additionally, members of the group may consist of oligonucleotides which may form mismatches with some or all members of a given set of template nucleic acids. But under appropriate conditions  
5 these primers can also participate in the priming. The term "consensus primers" refers to a primer or group of primers, which can be used for the priming of certain regions of related template nucleic acids. The characteristic of these regions is that their variability is significantly lower than the variability of  
10 the whole nucleic acid, i.e. they are conserved, therefore on these sequences selected consensus primers can do priming including the whole group of template nucleic acid sequences. The consensus primer is not necessarily a single primer, it can be a group of primers.

15 The term "thermostable polymerase enzyme" refers to an enzyme that is relatively stable at 95 °C and catalyses the polymerisation of nucleoside triphosphates to form primer extension products that are complementary to one of the nucleic acid strands of the target sequence. A purified thermostable  
20 polymerase enzyme is described in U.S. Pat. No. 4,889,818, incorporated herein by reference, and is commercially available for example from Applera.

In the present invention amplification of DNA is carried  
25 out by the polymerase chain reaction (PCR), disclosed in U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188.

In the present invention optimised PCR conditions have developed for the purposes of the amplification of large number of different HPV genotypes with optimisation of primer concentrations, primer sequences and cycling conditions. First  
5 part of the amplification amplifies with constantly growing stringency, with the goal, that the amplification of the genotypes, for which the primers contain more mismatch nucleotides, could start to amplify with the same efficacy than the other genotypes, but later the growing binding temperature  
10 shifts the reaction towards the use of the primers, which are in larger quantities. With an optimised mixture of primers this process - in theory - will shift the primer binding sequences toward a consensus sequence, thus creating the possibility for the balanced sensitivity amplification of the genotypes.

15 Although the polymerase chain reaction is the preferred amplification method, the mentioned genomic regions and oligonucleotides can be used in any known method. For example the ligase chain reaction (Wu and Wallace 1989, Genomics 4:560-569), the TAS amplification system (Kwoh et  
20 al., 1989, Proc. Natl. Acad. Sci. USA 86:1173-1177), and self-sustained sequence replication (Guatelli et. al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878) can also be suitable for the correct amplification of the target sequence. Similarly, in the Q-beta-replicase system (Kramer and Lizardi, 1989, Nature  
25 339:401-402) sequence-specific probes can be amplified.

In the present invention the primers are chosen from group a more or less complementary sequences suitable to

amplfy HPV consensus amplicons. Effective priming is achived in the presence of mismatch nucleotide using carfully dersigned annealing temperature and relative concentrations of the primres.

5 In a preferred embodiment of the present invention, the primers of the invention (SEQ. ID. NO: 1-40, 70-72) are used with the known primers (SEQ. ID. NO: 73-75) in the form of suitable reagents. This allows the detection of an extended set of HPV genotypes, at least 47 known genotypes. It can be seen in  
10 example 4, that the amplification of the HPV-35 genotype according to the invention can be carried out including the primer SEQ. ID. NO. 37 in the reaction. Without this primer including only the known primers in the reaction the HPV-35 genotype is not amplified. Another aspect of the invention  
15 relates to type-specific primers for the HPV L1 gene, which include one of the nucleotide sequences described in SEQ. ID. NO: 1-36 sequences.

Another aspect of the invention relates to the mixture of primers including the L1C1, L1C2 or newL1C2 primers and  
20 primers which are chosen form SEQ. ID. NO: 1-40, 70-72 Moreover, the invention relates to the application of such mixture of primers for the amplification of HPV 3, 4, 6, 7, 9, 10, 11, 12, 13, 14, 16, 18, 20, 24, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39, 39, 40, 41, 42, 44, 45, 51, 52, 53, 54, 55, 56, 58,  
25 49, 60, 61, 66, 67, 68, 72, 74 or 77 genotypes.

Another aspect of the invention relates to the amplicons produced by amplification using the mixture of primers of the

invention, mentioned above, with the exception of the HPV-6, -11, -16, -18, -31, -33, -42, -52, and -58 amplicons.

An essential element of the present invention is the presence of the generic and type-specific genomic segments in the amplicons. These genomic segments enable realisation of the highly specific hybridisation and detection. Therefore the present invention relates also to a genomic segment of the amplicons, characterised by a genotype-specific, diverse genomic segment stretching from the 3' end of the amplicon (in 3' - 5' direction) from the -80 bp to -30 bp. These genomic segments are about 40 bp long, double-stranded DNA sequences, given in the SEQ. ID. NO: 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111 sequences.

Another aspect of the present invention relates to another genomic segment of the amplicons, stretching 3'-5' from the 3' end of the amplicon from the -150 bp to -105 bp, and characterised by highly conserved low complexity sequences between genotypes, which shows generic HPV genus specificity. These genomic segments are double-stranded DNA, usually contain 23 bp, and their upper strand has one of the following sequences: SEQ. ID. NO: 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110.

During hybridisation detection of the amplicons, generic or type-specific hybridisation probes are used, designed for the genomic segments mentioned above. The generic oligonucleotide probes are generally applicable for detection of the HPV amplicon, that is the amplified HPV DNA, while the type-specific



probes can be used for further typing thereof, that is for detecting the individual genotypes. Both hybridisation probes can be DNA, RNA or PNA in nature.

The generic probes used in the method of the invention  
5 have similar properties to the consensus primers, with the difference, that the 5' end is not preferred for the position of mismatch nucleotide pairs. In present invention they are used as probes, these generic probes can be used both as hybridisation probes and primers.

10 Therefore the invention relates to the generic (consensus) hybridisation probes or primers, which include one of the sequences listed in the SEQ. ID. NO: 41-49 sequences.

In a preferred method of the invention the following probes are used as generic probes: SEQ. ID. NO: 41-49.

15 In case of type-specific probes the probes are 100% complementary to the sequence of the corresponding genotype. During their design it is important to exclude the possibility, whether other genotypes show high level complementarity with the probe or part of it. Since the type-specific segment is about  
20 40 bp long in the amplicons of the invention, it is possible to select even overlapping probe-sequences, which are the most adequate both theoretically and experimentally. It is demonstrated in Example 5 that adequate probes could be designed and used, which have high specificity (compared to the  
25 investigated 70 genotypes), and they keep their specificity even at room-temperature with the hybridisation conditions used. Since the hybridisation of probes is suitably specific in identical

hybridisation conditions, the mixture of the probes can also be used. Therefore from practical point of view more uniform reaction conditions can be used. Therefore the invention relates to the sequences of the type-specific probes, which can be used  
5 in HPV amplification and detection and genotyping tests, and include one of the sequences listed in SEQ. ID. NO: 50-67.

Although the invention relates to any embodiment of the hybridisation, but commercially the solid phase hybridisation is preferred.

10 The so called solid phase (forward) hybridisation binds the probes to immobilized target nucleic acid (amplicon), while the reverse hybridisation binds the target nucleic acid (amplicon) to immobilized probes. Unbound reaction products are removed with different washing solutions in the process. In the first case  
15 the probe must be labelled suitably for later development, while in the reverse form the amplicon labelled. Both systems can be realized in microtiter plates. Since the capacity of immobilization is limited, in the present invention the forward hybridisation system is preferred because of the large number  
20 of the individual probes constituting the mixture of probes used.

The method described in US 6,214,979 can similarly be applicable, where the probes are added to the reaction during amplification. During the process the 5'-3' exonuclease activity of the Taq polymerase decomposes the probes, and detecting  
25 the produced decomposition products can be used for detecting the presence of the target nucleic acid. But other, mostly hybridisation based, so called real-time detection systems are

also known, but these differ only in their implementation and detection method, and not in a theoretically different realization of the sequence-specific probe-amplicon binding.

For the immobilization the amplicons can be labelled.  
5 From the various possibilities in the present invention the biotin labelling of the primers and the use of labelled primer in amplification reactions preferred. In the presence of avidin or streptavidin absorbed to solid phase biotin results in the immobilization of the amplicon, as a consequence of the highly  
10 specific and very stable avidin-biotin binding. In a given reaction only primers hybridising to one or the other strand are biotinilated, so the other strand can be removed before hybridisation.

For detection purposes the probes can be labelled, which  
15 labels can be detected by various methods, for example by detection methods which are based on fluorescence, radioactivity, colorimetry, X-ray diffraction, absorption, magnetism, enzyme activity etc. Therefore the suitable labelling may include but are not limited to the following: fluorophores,  
20 chromophores, isotopes, electrodense substances, enzymes or ligands able to form specific binding. Combination of the systems mentioned above can also be used. In the present invention the specific binding of fluorescein with anti-fluorescein-HRPO antibody which is detected by the horseradish  
25 peroxidase oxidation reaction in the presence of HPPA substrate and  $H_2O_2$  is preferred (see Example 2). In the present invention biotinilated forward or reverse primers are used. Both the

labelling of the probes and the anti-fluorescein-HRPO are commercially available. Chemicals necessary for washings and the various solutions are also generally available. System using alkaline phosphatase, or any other enzyme, which activity can  
5 be detected, can also be constructed or used. Besides the fluorescent detection luminometry and colorimetry are also acceptable detection methods, for medical diagnostic application of the system.

Including internal control during diagnostic application of  
10 the method of the invention gives the possibility to recognize false negative reactions and from a diagnostic point of view it is preferred. Various artificial or natural DNA source can be used for internal control. Those systems are preferred, which do not increase the number of the primers used in the reaction, and  
15 the amount and analytical properties of the internal control target nucleic acid are suitably standardized. In the present invention an artificial nucleic acid sequence (SEQ. ID. NO: 68) is added to the sample in the form of recombinant plasmid (Example 6). In the present invention detecting of the internal  
20 control is carried out parallel with the hybridisation detection of HPV DNA, and only the development of the substrates is separated. The probe is digitoxigenin labelled (SEQ. ID. NO: 69), and detectable with alkaline phosphatase conjugated anti-digitoxigenin antibody. However other detection techniques are  
25 also suitable for detection of internal probe.

But detecting of the internal control can also be carried out on the basis of mobility differences, using agarose gel-electrophoresis or other suitable technique.

For the amplification and the detection of the HPV DNA  
5 the method of the present invention is suitable to produce a harmonized unit of the reagents (kit). In this form the kit can contain all the following reagents, or any combination of them, and other reagents: primers, mixture of primers, buffers, thermostable polymerase, positive control HPV DNA, non-HPV  
10 DNA, internal control DNA, probes or mixture of probes, antibody-enzyme conjugate.

The description of sequences of the primers and probes of the invention is only illustrative. Many variants of both the generic and the type-specific probes can be designed using the  
15 generic or type-specific HPV genomic region, for those skilled in the art, therefore the variations as far as they are chosen from the genomic region of the invention are covered by the scope of the present invention.

The invention is presented in more details with the  
20 following examples. Although the method, which is the basis of the invention is applicable to the amplification of any HPV genome, in the following examples only the genital HPV genomes are used, which are of greater medical importance. It is to be noted, that the examples are only illustrative, and are  
25 not to be construed as limiting the scope of the invention.

### Example 1

### Synthesis of oligonucleotide primers

The oligonucleotide primers used in the method of the invention were commercial sources (IDT, USA). The primers were synthesised with a 5' amino group. NHS-ester was used  
5 for biotin, fluorescein and digitoxygenin labelling. The labelled nucleotides were HPLC purified.

### Example 2

#### Processing of the specimens, preparation of DNA

10 Samples were taken by gynaecologists using cytobrush, samples are transported in PBS (10 mM Phosphate buffered Saline pH=7,4, Sigma, NaCl 138 mM, KCl 2,7 mM) solution. Pre-treatment of the samples was done in the sampling tubes: before lysing, the samples were centrifuged (2000 g, 10  
15 minutes), supernatants were discarded, and 1 ml PBS solution was added, vortexed, centrifuged again, discarding the supernatant. In the end of the process 250 µl lysing solution was added to the samples (0,5 mg/ml proteinase-K, 0,01 M TRIS-HCl pH=8, 0,001 M EDTA pH=8, in distilled water), which  
20 solution contains the internal control of the HPV test (SEQ. ID. NO: 68), and vortexed and incubated for 30 minutes at 56 °C.

From this point all liquid handling tasks were carried out on a TECAN RSP150 robot.,.: 200 µl binding solution (5,5 M GUSCN, 20 mM EDTA, 10 mM TRIS-HCl pH=6,5, 65 mM dithiothreitol, 40  
25 g/l silica, SIGMA Cat. No.: 28,851-3, distilled water) was added, and the silica was separated by vacuum filtration from the soluble components. Filtration is used again to wash the silica

twice with 200 µl binding solution without silica (5,5 M GUSCN, 20 mM EDTA, 10 mM TRIS-HCl pH=6,5, 65 mM dithiothreitol, , distilled water), and 200 µl washing solution is used twice ( 25% isopropyl-alcohol, 25% 96%-ethanol, 50% distilled water, 0,1 M NaCl), finally with 200 µl 96%-ethanol is applied. After air drying the silica, DNA was eluted in 200 µl 10 mM TRIS-solution pH=8,0. Eluted DNA is stored frozen at -20 °C until further use.

### Example 3

#### 10 General description of the HPV detection

##### Amplification

The total reaction-volume was 25 µl, including the following components: 10 µl DNA, 2,5 µl 10X polymerase buffer (final concentration: 10 mM TRIS-HCl (pH=9,0), 50 mM KCl, 0,1% Triton X-100 (Promega)), 2 mM MgCl<sub>2</sub>, 250 µM each dNTP (ATP, CTP, GTP, TTP), 4 µM of a primer-mixture: SEQ. ID. NO: 35, 37-40, 73-75, and 1U Taq DNA polymerase (Promega). The reaction was carried out in GeneAmp 9700 PCR thermal cycler, with the following parameters:

20 Cycle 1: 4 minutes at 95 °C;

Cycles 2-40: 30 seconds at 94 °C, 1 minute at 48 °C, and 45 seconds at 72 °C;

Cycle 41: 3 minutes at 72 °C.

#### 25 Hybridisation and detection

Hybridisation was carried out on solid phase. 24 hours earlier the black, 96-well polystyrene plates (Costar) were coated

with streptavidin (0,02 mg/ml streptavidin in PBS solution). Plates were incubated at room temperature, and 24 hours later the plates were washed twice with 250 µl washing solution [25 mM TRIS pH=7,5, 125 mM NaCl, 20 mM MgCl<sub>2</sub>, 3% Tween-20].

5 20 µl of the product of the PCR-reaction is diluted with 140 µl distilled water, and 5 µl from this solution was mixed with 45 µl binding puffer [25 mM TRIS pH=7,5, 125 mM NaCl, 5 mM EDTA-Na<sub>2</sub>, 5X Denhardt's solution, 0,1% Tween-20] and dispensed into the wells of the streptavidin coated plate. The

10 reaction was incubated at room temperature for 30 minutes, with constant shaking. Then 50 µl elution buffer [100 mM NaOH, 300 mM NaCl] was added to the mixture, incubated for 3 minutes at room temperature, and the plates were washed 3 times with 250 µl washing solution [25 mM TRIS pH=7,5, 125

15 mM NaCl, 20 mM MgCl<sub>2</sub>, 3% Tween-20]. After the washing 50 µl hybridisation buffer (5xSSC (0,3 M Na-citrate pH=7, 3 M NaCl), 1xDenhardt's solution, 0,1% SDS], containing fluorescein labelled probes (5 nM per probe) was added to the wells. The mixture was incubated for 30 minutes at 50 °C with constant

20 shaking, and washed 6 times with 250 µl high stringency washing solution [0,05 x SSC, 0,3% Tween-20]. After this 50 µl conjugation buffer [25 mM TRIS pH=7,5, 125 mM NaCl, 2 mM MgCl<sub>2</sub>, 0,3% Tween-20, 1% BSA], containing Anti-Fluorescence-POD (Roche) antibody (0,0015 E/reaction) was added to the

25 reaction. Plates were incubated for 30 minutes at room temperature with shaking, and washed 6 times with 250 µl high stringency washing solution [25 mM TRIS pH=7,5, 125 mM



NaCl, 20 mM MgCl<sub>2</sub>, 3% Tween-20]. For development 135 µl substrate solution (5 volume [45 mM hydroxyphenyl-propionic acid (HPPA), dissolved in 0,1 M TRIS-HCl pH=9,0 buffer], + 1 volume [0,6 g/l H<sub>2</sub>O<sub>2</sub> in 20 mM citrate-phosphate buffer]) was added. To stop the reaction 65 µl stop solution [0,75 M glycine pH=10,3] was added to the reaction mixture after 20 minutes. The fluorescent signal was measured with SpectraMax plate-fluorometer at 324/410 nm. Samples were considered positive if their value was higher than three times of the average of 3 parallel negative control sample value.

#### Example 4

##### Comparative study of amplification

Samples were spiked at 10 ng/reaction by plasmids containing cloned HPV L1 region from different genotypes and used to amplify and detect HPV DNA by method of the invention. PCR reaction and hybridisation was carried out according to the description of Example 3, with the difference that the composition of the primers were changed. The reaction without the L1F2 (SEQ. ID. NO: 37) did not result in amplification with the genotype HPV 35, while using the L1F2 primer resulted in the effective detection of the genotype HPV 35.

#### 25 Example 5

##### Detecting several HPV genotypes

Samples were spiked at 10 ng/reaction by plasmids containing cloned HPV L1 region from different genotypes and used to amplify and detect HPV DNA by method of the invention. PCR reaction and hybridisation was carried out according to the description of Example 3. Amplification and typing of the following HPV genotypes were attempted: 1-24, 26-42, 45, 47-68, 72-74, 76-77, 86. The amplification of the following genotypes were demonstrated with agarose gel-electrophoresis: 3, 6-7, 10-11, 13-14, 16, 18, 20, 24, 26, 29, 30-36, 39-40, 42, 45, 51, 52-55, 58-62, 66-68, 72. Using the mixture of the SEQ. ID. NO: 41-49 genus-specific hybridisation probes (using the conditions described in Example 3) the following genotypes were detectable: 3-4, 6-7, 9-14, 16, 18, 20, 24, 26, 29, 30-37, 39-42, 45, 51, 52-55, 58-62, 66-68, 72, 74, 77. Data show, that a portion of the genotypes can only be detected by hybridisation, which is not surprising, since hybridisation is about 10-100-times more sensitive than agarose gel-electrophoresis. It can also be seen from the data, that the genus-specific hybridisation did detect all agarose gel-electrophoresis positive genotypes indicating its true genus-specific nature.

### Example 6

#### Detecting the HPV-35 type

Samples were spiked at 10 ng/reaction by plasmids containing cloned HPV L1 region from different genotypes and used to amplify and detect HPV DNA by method of the

invention. PCR reaction and hybridisation were carried out according to the description of Example 3. Hybridisation probe was the oligonucleotide designed for the genotype HPV 35 (SEQ. ID. NO: 58). The detection of amplicons of the following  
5 genotypes was attempted: 3-4, 6-7, 9-14, 16, 18, 20, 24, 26, 29, 30-37, 39-42, 45, 51, 52-55, 58-62, 66-68, 72, 74, 77. The probe detected only the corresponding HPV 35 genotype amplicon.

#### 10 Example 7

##### HPV detection with internal control

Detection of the samples prepared according to Example 2 was carried out according to Example 3, with the difference that the probe of the internal control labelled with digitoxinigenin (its  
15 amount was the same as the type-specific probes) was used with the type-specific probes, and the anti-fluorescein-POD and the anti- $\alpha$ -ALP [1:2000, Jackson Immuno Research] antibodies were simultaneously present in the conjugation step. After the development of the POD reaction (see Example 2),  
20 development of ALP was carried out according to the following: the substrate solution was 6,25 mg/100 ml 4-methyl-umbelliferil-phosphate in 100 mM TRIS pH=9,0, 0,5 mM  $MgCl_2$  buffer. After the development of the HPPA the microtiter plate was washed once with [25 mM TRIS pH=7,5, 125 mM NaCl, 20  
25 mM  $MgCl_2$ , 3% Tween-20], and 150  $\mu$ l substrate solution was added to each reaction wells. After 30 minutes incubation the fluorescent signal was measured with SpectraMax plate-

fluorometer at 355/460 nm. Samples were considered positive if their value was higher than three times the average of 3 parallel negative control sample value.

Type-specific probes detected the adequate types only.

- 5 Detection of the internal control was positive in each reaction, except in those reactions, where strong competition between the HPV amplification and the internal control occurred.. There were no inhibited reaction (HPV DNA or internal control DNA amplified in all samples). The internal control adequately
- 10 excluded the possibility of false negative results.

## CLAIMS

1. Consensus primers for the human papillomavirus (HPV) L1 gene, wherein said primers consist of one of the following nucleotide sequences: SEQ. ID. NO: 37-40 or SEQ. ID. NO: 70-72.

2. Type-specific primers for the human papillomavirus (HPV) L1 gene, wherein said primers consist of one of the following nucleotide sequences: SEQ. ID. NO: 1-36.

3. Amplification primer-mixture, wherein said mixture consists of one or more of the following primers of SEQ. ID. NO: 37-40, 70-72 and/or SEQ. ID. NO: 1-36, and the L1C1, L1C2 or newL1C2 primers.

4. Use of the primer mixture of Claim 3 for the amplification of the 3, 4, 6, 7, 9, 10, 11, 12, 13, 14, 16, 18, 20, 24, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39, 39, 40, 41, 42, 44, 45, 51, 52, 53, 54, 55, 56, 58, 49, 60, 61, 66, 67, 68, 72, 74 or 77 genotypes of the human papillomavirus.

5. Amplicon, which can be prepared with amplification using the primer-mixture of Claim 3, except the amplicons of HPV-6, -11, -16, -18, -31, -33, -42, -52, and -58 types.

6. Amplicon according to Claim 5, the nucleotide sequence of which includes one of the sequences of the SEQ. ID. NO: 112-120 sequences.

7. Genomic region of the amplicons of 3, 4, 6, 7, 9, 10, 11, 12, 13, 14, 16, 18, 20, 24, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39, 39, 40, 41, 42, 44, 45, 51, 52, 53, 54, 55, 56, 58,

49, 60, 61, 66, 67, 68, 72, 74 or 77 genotypes which is a characteristic segment of the amplicons prepared by amplification using the primer-mixture of Claim 3, stretching from the 3' end of the amplicon from the -80 bp to -30 bp, and  
5 a diverse segment characteristic of the individual HPV genotypes.

8. Isolated double-stranded DNA-segment of Claim 7, which has one of the sequences hereunder: SEQ. ID. NO: 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107,  
10 109, 111.

9. Genomic segment of the amplicon prepared by amplification using the primer-mixture of Claim 3, stretching from the 3' end of the amplicon from the -150 bp to -105 bp, consensus segment for HPV.

15 10. Isolated double-stranded DNA-segment of Claim 9, which has one of the sequences listed hereunder: SEQ. ID. NO: 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110.

11. Hybridisation probe, which is HPV genotype-specific,  
20 and complementary to one of the sequences of Claim 8.

12. Hybridisation probe of Claim 11, which has one of the sequences listed hereunder: SEQ. ID. NO: 50-67.

13. Hybridisation probe or primer, which is HPV consensus probe or primer, and complementary to one of the  
25 sequences of Claim 10.

14. Hybridisation probe of Claim 13, which has one of the sequences listed hereunder: SEQ. ID. NO: 41-49.

15. Hybridisation probe of Claim 11 or 13, which is DNA, RNA or PNA.

16. Method for detecting many HPV genotypes from biological samples, comprising that:

5 a) the nucleic acid molecules extracted from the biological sample are amplified with a primer-mixture of Claim 3, as a result of which double-stranded amplified product(s) are prepared, which

b1) are either hybridised in stringent conditions to  
10 hybridisation probe of Claim 14, or to mixture thereof, and the HPV genotypes present in a given case are detected;

and/or

b2) are hybridised in stringent conditions to the mixture of the probes of Claim 12, and the HPV genotype-groups are  
15 separated and detected;

and/or

b3) are hybridised in stringent conditions to probe of Claim 12, and the HPV genotype present in a given case are detected and typed.

20 17. Method of Claim 16, comprising that the low- and high-risk HPV genotype-groups are detected.

18. Method of Claim 16 or 17, comprising that in the method a synthetic oligonucleotide is also detected as internal control.

25 19. Method of Claim 18, comprising that SEQ. ID. NO: 68 sequence is used as internal control, and for detecting this SEQ. ID. NO: 69 is used as hybridisation probe.

20. Reagent kit for detecting and typing HPV, which includes

- i) primers of Claims 1, 2 or 3;
- ii) optionally internal control primer;
- 5 iii) hybridisation probes of Claim 12 or 14;
- iv) optionally hybridisation probes detecting the internal control; and
- v) the usual amplification and hybridisation reagents.



## SEQUENCE LISTING

<110> Jeney, Csaba  
Takács, Tibor

<120> Amplification and hybridisation method for detecting and typing of human papilloma virus

<140> PCT/HU03/00020

<141> 2003-03-10

<150> HU P0200981

<151> 2002-03-14

<160> 120

<170> PatentIn version 3.1

<210> 1

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer (L1CF6)

<400> 1

cgtaaacgta ttcccttatt tttt

24

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer (L1CR6)

<400> 2

caatacaggg tattttaaggt g

21

<210> 3

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer (L1CF11)

<400> 3

cgtaaacgta ttcccttatt tttta

25

<210> 4

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (L1CR11)

<400> 4  
caatatagag tgtttagggt a 21  
<210> 5  
<211> 24  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer (L1CF42)

<400> 5  
cgtaaacctg taccatattt tttt 24

<210> 6  
<211> 21  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer (L1CR42)

<400> 6  
cagtacagag tatttagagt t 21

<210> 7  
<211> 24  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer (L1CF44)

<400> 7  
cgtaaactgtg tttccttggt tttt 24

<210> 8  
<211> 21  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer (L1CR44)

<400> 8  
caatataggg tttttaagat g 21

<210> 9  
<211> 24  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer (L1CF16)

<400> 9

cgtaaacggtt taccatatattt tttt

<210> 10  
 <211> 21  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer (L1CR16)

<400> 10  
 caatacaggg tatttagaat a 21

<210> 11  
 <211> 25  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer (L1CF18)

<400> 11  
 cgtaaacgtg ttccctatatt ttttg 25

<210> 12  
 <211> 21  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer (L1CR18)

<400> 12  
 caatatagag tatttagggt g 21

<210> 13  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> PCR primer (L1CF31)

<400> 13  
 cgtaaacgtg tatcatatatt tttt , 24

<210> 14  
 <211> 21  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> PCR primer (L1CR31)

<400> 14  
 caatataggg tatttagggt t 21

<210> 15  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF33)

<400> 15  
cgtaaacggt ttccatattt tttta

25

<210> 16  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CR33)

<400> 16  
caatataggg ttttttaggt c

21

<210> 17  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF35)

<400> 17  
cgtaaagcta tcccatattt tttt

24

<210> 18  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CR35)

<400> 18  
caatacagag tatttagagt a

21

<210> 19  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF39)

<400> 19  
cgtaaacgta ttccctattt ttttc

25

<210> 20

<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CR39)

<400> 20  
caatataggg tatttcgcgt g

21

<210> 21  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF45)

<400> 21  
cgtaaacgta ttccctatatt ttttg

25

<210> 22  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CR45)

<400> 22  
cagtataggg tgtttagagt a

21

<210> 23  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF51)

<400> 23  
cgtaaacgta taccctatatt tttt

24

<210> 24  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CR51)

<400> 24  
caatacaggg tatttagggt a

21

<210> 25  
<211> 25

<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF52)

<400> 25  
gcgtaaacgt tttccatatt ttttt 25

<210> 26  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CR52)

<400> 26  
caatacaggg tattttagaat t 21

<210> 27  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF56)

<400> 27  
cgtaaacgta ttccctatatt ttttt 25

<210> 28  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CR56)

<400> 28  
tcaatatagg gtatttaggg ta 22

<210> 29  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer (L1CF58)

<400> 29  
acgtaaacgt tttccatatt ttttt 25

<210> 30  
<211> 21  
<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1CR58)

<400> 30

cagtataggg tcttttagggt g

21

<210> 31

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1CF59)

<400> 31

cgtaaacgtg ttccctatatt tttt

24

<210> 32

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1CR59)

<400> 32

caatacagag tattttagggt t

21

<210> 33

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1CF66)

<400> 33

ccgtaaacgt attccctatt ttttt

25

<210> 34

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1CR66)

<400> 34

cagtatagag tgtttagggt a

21

<210> 35

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1CF68)

<400> 35

cgtaaacacc ttccttattt tttt

24

<210> 36

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1CR68)

<400> 36

caatacagag tgtttaggg t

21

<210> 37

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1F2)

<400> 37

cgtaaagcta taccatattt tttt

24

<210> 38

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1F3)

<400> 38

cgtaaacacg ttccatattt tttt

24

<210> 39

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1F4)

<400> 39

cgtaaacgtg tttcctattt tttt

24

<210> 40

<211> 21

<212> DNA

<213> artificial sequence



<220>  
<223> PCR primer (L1R2)  
  
<400> 40  
cagtacagag tttttagaat t 21  
  
<210> 41  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK1)  
  
<400> 41  
cgcaccaaca tattttatta tgg 23  
  
<210> 42  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK2)  
  
<400> 42  
cgcacaagca tctattatta tgc 23  
  
<210> 43  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK3)  
  
<400> 43  
cgcacaagca tattttatca tgc 23  
  
<210> 44  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK4)  
  
<400> 44  
cgcaccagta tattttatca tgc 23  
  
<210> 45  
<211> 23  
<212> DNA  
<213> artificial sequence

<220>  
<223> genus-specific hybridisation probe (PK5)  
  
<400> 45  
cgcacagca ttactatca tgc 23  
  
<210> 46  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK6)  
  
<400> 46  
cgcaccaact acttttacca tgc 23  
  
<210> 47  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK7)  
  
<400> 47  
cgtaccagta ttttctacca cgc 23  
  
<210> 48  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK8)  
  
<400> 48  
cgcacaggca tatattacta tgc 23  
  
<210> 49  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> genus-specific hybridisation probe (PK9)  
  
<400> 49  
cgcaccaaca tatattatca tgc 23  
  
<210> 50  
<211> 20  
<212> DNA  
<213> artificial sequence  
  
<220>

<223> HPV-6 type-specific hybridisation probe (P6)

<400> 50  
ttttgttagc ccgttttatg 20

<210> 51  
<211> 23  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-11 type-specific hybridisation probe (P11)

<400> 51  
acaactgttt ttgttaactt ttt 23

<210> 52  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-42 type-specific hybridisation probe (P42)

<400> 52  
tgtcttatttt ggcctttttg 20

<210> 53  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-44 type-specific hybridisation probe (P44)

<400> 53  
gtcttgtttg ctggtcgtat 20

<210> 54  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-16 type-specific hybridisation probe (P16)

<400> 54  
ctaataatttt gttattgtta ggttt 25

<210> 55  
<211> 19  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-18 type-specific hybridisation probe (P18)

<400> 55  
tatacctgctt attgccacc 19

<210> 56  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-31 type-specific hybridisation probe (P31)

<400> 56  
ggattgtcag atttaggtat gg 22

<210> 57

<211> 23  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-33 type-specific hybridisation probe (P33)

<400> 57  
tttttagcgt tagtaggatt ttt 23

<210> 58  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-35 type-specific hybridisation probe (P35)

<400> 58  
tgctatttta ttagaatcctt gtttt 25

<210> 59  
<211> 19  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-39 type-specific hybridisation probe (P39)

<400> 59  
accaccattc atacccact 19

<210> 60  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-45 type-specific hybridisation probe (P45)

<400> 60  
acctgcacca ttaggtacaa 20

<210> 61  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-51 type-specific hybridisation probe (P51)

<400> 61  
gcggttgaggt ttaggtatt 20

<210> 62  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-52 type-specific hybridisation probe (P52)

<400> 62  
caattaccac tactggtgtt t 21

<210> 63  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-56 type-specific hybridisation probe (P56)

<400> 63  
tgtttggtttt ggtattgtcc t 21

<210> 64  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-58 type-specific hybridisation probe (P58)

<400> 64  
gttattggga cttttgatgg 20

<210> 65  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> HPV-59 type-specific hybridisation probe (P59)

<400> 65  
 tcctgtctac cattaccacc 20

<210> 66  
 <211> 20  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> HPV-66 type-specific hybridisation probe (P66)

<400> 66  
 ttggtaccag atttggaac 20

<210> 67  
 <211> 20  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> HPV-68 type-specific hybridisation probe (P68)

<400> 67  
 cccagacata ggaaccttaa 20

<210> 68  
 <211> 198  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> Inside control oligonucleotide molecule

<400> 68  
 cgtaaacggt ttccctatTT ttttagtcaa tgagacgggt aatgacgata cagtatgacg 60  
 atagagtaga tagatagaga tagataccca tatacagata atgacataga tccccataga 120  
 cagtttatac agatcagtag cagtttttat atatgagatg atgataggac acaccagcaa 180  
 tatagggtat ttagggta 198

<210> 69  
 <211> 21  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> Inside control amplicon-specific hybridisation probe (IC-P1)

<400> 69  
 tgacatagat ccccatagac a 21

<210> 70  
 <211> 24  
 <212> DNA

213> Artificial sequence

<220>

<223> PCR primer (L1F5)

<400> 70

cgtaaacgta ttccctatatt tttt

24

<210> 71

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1F6)

<400> 71

cgtaaacggt ttccatattt tttt

24

<210> 72

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1R3)

<400> 72

cagtacagag ttttttagagt g

21

<210> 73

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1C1)

<400> 73

cgtaaacggt ttccctatatt tttt

24

<210> 74

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (L1C2)

<400> 74

caatacagag tatttagggt a

21

<210> 75

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer (new L1C2)

<400> 75

caatataggg tatttaggt a

21

<210> 76

<211> 23

<212> DNA

<213> Human papillomavirus type 6

<220>

<221> misc\_feature

<223> HPV-6 amplicon genus-specific probe binding site

<400> 76

cgcaccaaca tattttatca tgc

23

<210> 77

<211> 39

<212> DNA

<213> Human papillomavirus type 6

<220>

<221> misc\_feature

<223> HPV-6 amplicon type-specific probe binding site

<400> 77

ccttattttt ccataaaacg ggctaacaaa actgttgtg

39

<210> 78

<211> 23

<212> DNA

<213> Human papillomavirus type 11

<220>

<221> misc\_feature

<223> HPV-11 amplicon genus-specific probe binding site

<400> 78

cgcaccaaca tattttatca tgc

23

<210> 79

<211> 39

<212> DNA

<213> Human papillomavirus type 11

<220>

<221> misc\_feature

<223> HPV-11 amplicon type-specific probe binding site

<400> 79

ccatattact ctatcaaaaa agttaacaaa acagttgta

39



<210> 80  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 42  
  
<220>  
<221> misc\_feature  
<223> HPV-42 amplicon genus-specific probe binding site  
  
<400> 80  
cgcaccaact actttttacca tgc 23  
  
<210> 81  
<211> 42  
<212> DNA  
<213> Human papillomavirus type 42  
  
<220>  
<221> misc\_feature  
<223> HPV-42 amplicon type-specific probe binding site  
  
<400> 81  
ccttattact ctattacaaa aagccaaata agacatctat cc 42  
  
<210> 82  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 44  
  
<220>  
<221> misc\_feature  
<223> HPV-44 amplicon genus-specific probe binding site  
  
<400> 82  
cgcaccaaca tatattacca tgc 23  
  
<210> 83  
<211> 39  
<212> DNA  
<213> Human papillomavirus type 44  
  
<220>  
<221> misc\_feature  
<223> HPV-44 amplicon type-specific probe binding site  
  
<400> 83  
ccttattttg ccatacgacc agcaaacaag acacttgtg 39  
  
<210> 84  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 16  
  
<220>  
<221> misc\_feature  
<223> HPV-16 amplicon genus-specific probe binding site

<400> 84  
cgcaaaaca tatattatca tgc 23

<210> 85  
<211> 40  
<212> DNA  
<213> Human papillomavirus type 16

<220>  
<221> misc\_feature  
<223> HPV-16 amplicon type-specific probe binding site

<400> 85  
ttttcctatt aaaaaaccta acaataacaa aatattagtt 40

<210> 86  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 18

<220>  
<221> misc\_feature  
<223> HPV-18 amplicon genus-specific probe binding site

<400> 86  
cccacaagca tattttatca tgc 23

<210> 87  
<211> 41  
<212> DNA  
<213> Human papillomavirus type 18

<220>  
<221> misc\_feature  
<223> HPV-18 amplicon type-specific probe binding site

<400> 87  
atttttaggggt tcctgcaggt ggtggcaata agcaggatat t 41

<210> 88  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 31

<220>  
<221> misc\_feature  
<223> HPV-31 amplicon genus-specific probe binding site

<400> 88  
cgaaccaaca tatattatca cgc 23

<210> 89  
<211> 40  
<212> DNA  
<213> Human papillomavirus type 31

<220>  
<221> misc\_feature  
<223> HPV -31 amplicon type-specific probe binding site

<400> 89  
ttccatacct aaatctgaca atcctaataaa aatagttgta 40

<210> 90  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 33

<220>  
<221> misc\_feature  
<223> HPV-33 amplicon genus-specific probe binding site

<400> 90  
cgcacaagca tttattatta tgc 23

<210> 91  
<211> 40  
<212> DNA  
<213> Human papillomavirus type 33

<220>  
<221> misc\_feature  
<223> HPV-33 amplicon type-specific probe binding site

<400> 91  
ttctattaataa aatcctacta acgctaataaa attattggta 40

<210> 92  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 35

<220>  
<221> misc\_feature  
<223> :HPV-35 amplicon genus-specific probe binding site

<400> 92  
cgcacaaaca tctactatca tgc 23

<210> 93  
<211> 40  
<212> DNA  
<213> Human papillomavirus type 35

<220>  
<221> misc\_feature  
<223> HPV-35 amplicon type-specific probe binding site

<400> 93  
ctatgctatt aaaaaacaag attctaataa aatagcagta 40

<210> 94  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 39  
  
<220>  
<221> misc\_feature  
<223> HPV-39 amplicon genus-specific probe binding site  
  
<400> 94  
cgcacaggca tatattatta tgc 23  
  
<210> 95  
<211> 41  
<212> DNA  
<213> Human papillomavirus type 39  
  
<220>  
<221> misc\_feature  
<223> HPV-39 amplicon type-specific probe binding site  
  
<400> 95  
atatttaaagt gggatatgaat ggtggctgca agcaggacat t 41  
  
<210> 96  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 45  
  
<220>  
<221> misc\_feature  
<223> HPV-45 amplicon genus-specific probe binding site  
  
<400> 96  
cgcacagca tattttatca tgc 23  
  
<210> 97  
<211> 40  
<212> DNA  
<213> Human papillomavirus type 45  
  
<220>  
<221> misc\_feature  
<223> HPV-45 amplicon type-specific probe binding site  
  
<400> 97  
taggggtgta cctaattggtg caggtaataa acaggctggt 40  
  
<210> 98  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 51  
  
<220>  
<221> misc\_feature  
<223> HPV-51 amplicon genus-specific probe binding site

<400> 98  
cgcaccggca tatattacta tgc 23

<210> 99  
<211> 40  
<212> DNA  
<213> Human papillomavirus type 51

<220>  
<221> misc\_feature  
<223> HPV-51 amplicon type-specific probe binding site

<400> 99  
ctattttcca atacctaaaa cctcaacgcg tgctgctatt 40

<210> 100  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 52

<220>  
<221> misc\_feature  
<223> HPV-52 amplicon genus-specific probe binding site

<400> 100  
cgcacaagca tctattatta tgc 23

<210> 101  
<211> 41  
<212> DNA  
<213> Human papillomavirus type 52

<220>  
<221> misc\_feature  
<223> HPV-52 amplicon type-specific probe binding site

<400> 101  
taaaaacacc agtagtggtgta atggtaaaaa agtttttagtt c 41

<210> 102  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 56

<220>  
<221> misc\_feature  
<223> HPV-56 amplicon genus-specific probe binding site

<400> 102  
cgactagta tatttttatca tgc 23

<210> 103  
<211> 41  
<212> DNA  
<213> Human papillomavirus type 56

<220>  
<221> misc\_feature  
<223> HPV-56 amplicon type-specific probe binding site

<400> 103  
ctattactct gtgactaagg acaataccaa aacaaacatt c 41

<210> 104  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 58

<220>  
<221> misc\_feature  
<223> HPV-58 amplicon genus-specific probe binding site

<400> 104  
cgcacaagca tttattatta tgc 23

<210> 105  
<211> 41  
<212> DNA  
<213> Human papillomavirus type 58

<220>  
<221> misc\_feature  
<223> HPV-58 amplicon type-specific probe binding site

<400> 105  
ttccatcaaa agtcccaata acaataaaaa agtattagtt c 41

<210> 106  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 59

<220>  
<221> misc\_feature  
<223> HPV-59 amplicon genus-specific probe binding site

<400> 106  
cgtaccagta ttttctacca cgc 23

<210> 107  
<211> 41  
<212> DNA  
<213> Human papillomavirus type 59

<220>  
<221> misc\_feature  
<223> HPV-59 amplicon type-specific probe binding site

<400> 107  
ttttaaaagta cctaaagggtg gtaatggtag acaggatggt c 41

<210> 108  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 66  
  
<220>  
<221> misc\_feature  
<223> HPV-66 amplicon genus-specific probe binding site  
  
<400> 108  
cgtaccagta tattttatca tgc 23  
  
<210> 109  
<211> 41  
<212> DNA  
<213> Human papillomavirus type 66  
  
<220>  
<221> misc\_feature  
<223> HPV-66 amplicon type-specific probe binding site  
  
<400> 109  
ttattactct gtttcctaat ctggtaccaa aacaaacatc c 41  
  
<210> 110  
<211> 23  
<212> DNA  
<213> Human papillomavirus type 68  
  
<220>  
<221> misc\_feature  
<223> HPV-68 amplicon genus-specific probe binding site  
  
<400> 110  
cgcactggca tgtattacta tgc 23  
  
<210> 111  
<211> 40  
<212> DNA  
<213> Human papillomavirus type 68  
  
<220>  
<221> misc\_feature  
<223> HPV-68 amplicon type-specific probe binding site  
  
<400> 111  
ttttaagggt cctatgtctg ggggccgcaa gcagggcatt 40  
  
<210> 112  
<211> 244  
<212> DNA  
<213> Human papillomavirus type 44  
  
<220>  
<221> misc\_feature  
<223> HPV-44 amplicon

<400> 112  
cgtaaactgt tttccttggt ttttgcagat gtggcggcct agtgaaaacc aggtatatgt 60  
gcctcctccc gccccagtat ccaaagtaat acctacggat gcctatgtca aacgcaccaa 120  
catatattac catgctagca gttctagact tcttgctgtg ggcaaccctt attttgccat 180  
acgaccagca aacaagacac ttgtgcctaa ggtttcggga tttcaatata ggggtttttaa 240  
gatg 244

<210> 113  
<211> 253  
<212> DNA  
<213> Human papillomavirus type 35

<220>  
<221> misc\_feature  
<223> HPV-35 amplicon

<400> 113  
cgtaaagcta tcccatatgt ttttgcagat gtctctgtgg cggcttaacg aagccactgt 60  
ctacctgcct ccagtgtcag tgtctaaggt tgtagcact gatgaatatg taacacgcac 120  
aaacatctac tatcatgcag gcagttctag gctattagct gtgggtcacc catactatgc 180  
tattaaaaaa caagattcta ataaaatagc agtaccacaag gtatctgggt tgcaatacag 240  
agtattttaga gta 253

<210> 114  
<211> 253  
<212> DNA  
<213> Human papillomavirus type 39

<220>  
<221> misc\_feature  
<223> HPV-39 amplicon

<400> 114  
cgtaaacgta ttccctatgt ttttgcagat ggctatgtgg cggcttagtg acagcatggt 60  
gtatttgcct ccaccttctg tggcgaaggt tgtcaatact gatgattatg ttacacgcac 120  
aggcatatat tattatgctg gcagctctag attattaaca gtaggacatc catattttta 180  
agtgggtatg aatgggtggc gcaagcagga cattccaaag gtgtctgcat atcaatatag 240  
ggattttcgc gtg 253

<210> 115  
<211> 256  
<212> DNA  
<213> Human papillomavirus type 45

<220>  
<221> misc\_feature



<223> HPV-45 amplicon

<400> 115

```
cgtaaacgta ttccctatTT ttttgcagat ggctttgtgg cggcctagtG acagtacggT    60
atatcttcca ccaccttctg tggccagagt tgtcagcact gatgattatg tgtctcgcac    120
aagcatatTT tatcatgcag gcagttcccg attattaact gtaggcaatc catatTTtag    180
ggttgtacct aatgggtgcag gtaataaaca ggctgttcct aaggtatccg catatcagta    240
taggggtgtt agagta                                         256
```

<210> 116

<211> 250

<212> DNA

<213> Human papillomavirus type 51

<220>

<221> misc\_feature

<223> HPV-51 amplicon

<400> 116

```
cgtaaacgta taccctatTT ttttacagat ggcattgtgg cgcactaatG acagcaaggT    60
gtatTTtcca cctgcacctg tgtctcgaat tgtgaataca gaagaatata tcacacgcac    120
cggcatatat tactatgcag gcagttccag actaataaca ttaggacatc cctatTTtcc    180
aatacctaaa acctcaacgc gtgctgctat tcctaaagta tctgcatttc aatacagggt    240
atTTtagggta                                         250
```

<210> 117

<211> 250

<212> DNA

<213> Human papillomavirus type 56

<220>

<221> misc\_feature

<223> HPV-56 amplicon

<400> 117

```
cgtaaacgta ttccctatTT ttttgcagat ggcgacgtgg cggcctagtG aaaataaggT    60
gtatctacct ccaacacctg tttcaaaggT tgtggcaacg gattcctatg taaaacgcac    120
tagtatatTT tatcatgcag gcagttcacg attgcttgcc gtaggacatc cctattactc    180
tgtgactaag gacaatacca aaacaaacat tcccaaagtt agtgcatatc aatatagggt    240
atTTtagggta                                         250
```

<210> 118

<211> 253

<212> DNA

<213> Human papillomavirus type 59

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; HPV-59 amplicon

&lt;400&gt; 118

```
ctgaaactgg ttcctatatt ttttacagat ggctctatgg cgttctagtg acaacaaggt      60
gtatctacct ccaccttcgg tagctaaggt tgtcagcact gatgagtatg tcaccggtac      120
cagtattttc taccacgcag gcagttccag acttccttaca gttggacatc catattttta      180
agtacctaaa ggtggtaatg gtagacagga tgttcctaag gtgtctgcat atcaatacag      240
agtatttagg gtt                                     253
```

&lt;210&gt; 119

&lt;211&gt; 250

&lt;212&gt; DNA

&lt;213&gt; Human papillomavirus type 66

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; HPV-66 amplicon

&lt;400&gt; 119

```
cgtaaacgta ttcctatatt ttttgcagat ggcgatgtgg cggcctagtg acaataaggt      60
gtacctacct ccaacacctg tttcaaaggt tgtggcaacg gatacatatg taaaacgtac      120
cagtatattt tatcatgcag gtagctctag gttgcttgct gttggccatc cttattactc      180
tgtttccaaa tctggtacca aaacaaacat ccctaaagtt agtgcataatc agtatagagt      240
gtttagggta                                     250
```

&lt;210&gt; 120

&lt;211&gt; 253

&lt;212&gt; DNA

&lt;213&gt; Human papillomavirus type 68

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; HPV-68 amplicon

&lt;400&gt; 120

```
cgtaaacacc ttccttattt ttttacagat ggcattgtgg cgagctagcg acaacatgg      60
gtattttgcct cccccctcag tggcgaaggt tgtcaatata gatgattatg tgacacgcac      120
tggcatgtat tactatgctg gtacatctag gttattaact gtaggccatc catattttta      180
ggttcctatg tctggggggc gcaagcaggg cattcctaag gtgtctgcat atcaatacag      240
agtgttttagg gtt                                     253
```

## INTERNATIONAL SEARCH REPORT

Internat .pplication No

PCT/HU 03/00020

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/70

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, EMBASE, WPI Data, PAJ, SEQUENCE SEARCH

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>KLETER BERNHARD ET AL: "Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus." JOURNAL OF CLINICAL MICROBIOLOGY, vol. 37, no. 8, August 1999 (1999-08), pages 2508-2517, XP002247920 ISSN: 0095-1137 page 2509, left-hand column, paragraph 3 -page 2511, right-hand column, line 3; figures 1-3; tables 1-5 --- -/--</p>	1-20

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

16 July 2003

Date of mailing of the international search report

04/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Seroz, T

## INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/HU 03/00020

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>KLETER B ET AL: "Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomavirus"</p> <p>AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 153, no. 6, December 1998 (1998-12), pages 1731-1739, XP002100812</p> <p>ISSN: 0002-9440</p> <p>page 1732, left-hand column, line 19 -page 1733, right-hand column, paragraph 3; figure 1; tables 1-3</p> <p>---</p>	1-20
X	<p>WO 99 14377 A (INNOGENETICS NV ;DELFTS DIAGNOSTIC LAB B V (NL); QUINT WIM (NL); K) 25 March 1999 (1999-03-25)</p> <p>claims 1-15; figures 1-6,9-11; examples 1-7; tables 1-12</p> <p>---</p>	1-20
X	<p>GRAVITT P E ET AL: "Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method"</p> <p>JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 36, no. 10, October 1998 (1998-10), pages 3020-3027, XP002202274</p> <p>ISSN: 0095-1137</p> <p>page 3020, right-hand column, paragraph 3 -page 3022, right-hand column, paragraph 1; figures 1,2; tables 1-3</p> <p>---</p>	1-20
A	<p>SNIJDDERS P J F ET AL: "THE USE OF GENERAL PRIMERS IN THE POLYMERASE CHAIN REACTION PERMITS THE DETECTION OF A BROAD SPECTRUM OF HUMAN PAPILLOMAVIRUS GENOTYPES"</p> <p>JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 71, 1990, pages 173-181, XP000255765</p> <p>ISSN: 0022-1317</p> <p>---</p>	
A	<p>JACOBS M V ET AL: "Group-specific differentiation between high and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes"</p> <p>JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 33, no. 4, April 1995 (1995-04), pages 901-905, XP002241733</p> <p>ISSN: 0095-1137</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HU 03/00020

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9914377	A	25-03-1999	AT 219153 T 15-06-2002
		AU 9743398 A	05-04-1999
		CA 2302146 A1	25-03-1999
		DE 69806024 D1	18-07-2002
		DE 69806024 T2	13-02-2003
		DK 1012348 T3	14-10-2002
		WO 9914377 A2	25-03-1999
		EP 1201771 A2	02-05-2002
		EP 1012348 A2	28-06-2000
		ES 2180207 T3	01-02-2003
		PT 1012348 T	29-11-2002
		US 6482588 B1	19-11-2002